{"entity":{"id":"decipher-bladder","kind":"drug","name":"Decipher Bladder","aka":["Decipher Bladder Genomic Subtyping Classifier"],"tldr":"A tissue test that sorts a bladder cancer into molecular types, which may help judge how it will respond to chemotherapy before surgery.","summary":"Veracyte states that \"Based on the expression of 219 genes\" the test \"classifies bladder tumors by molecular subtype\", that it is run on tissue from transurethral resection and \"is intended for patients with clinical stage T1 to T4a bladder cancer\", that it is a laboratory-developed test that \"has not been cleared or approved by the FDA\", and that it \"is covered by Medicare for patients with clinical stage T1-T4a bladder cancer\". The Medicare group policy for bladder classifiers (L38576) does not name it. The classifier was described in a study of muscle-invasive bladder cancer in which a single-sample genomic subtyping classifier predicted four consensus subtypes with 73 per cent accuracy and patients with basal tumours showed the most improvement in overall survival with neoadjuvant chemotherapy (Seiler 2017).","status":"established","asOf":"2026-11-04","links":[{"label":"Veracyte: Decipher Bladder","url":"https://www.veracyte.com/tests/decipher-bladder/providers/"},{"label":"CMS LCD L38576: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer","url":"https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38576"}],"tags":["test","rna"],"related":["decipher-prostate"],"cancers":["muscle-invasive-bladder-cancer","urothelial"],"sections":[],"technologies":["gene-expression-prognostic-assays","rna-seq"],"targets":[],"drugs":[],"companies":["veracyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-seiler-bladder-molecular-subtypes-chemotherapy-eur-urol-2017"],"journals":[],"dependsOn":[],"notes":[],"brand":"Decipher Bladder","modality":"Gene-expression molecular subtyping classifier (219 genes, bladder cancer)","mechanism":"Whole-transcriptome expression from tumour tissue taken at transurethral resection is reduced to 219 genes that assign a consensus molecular subtype of bladder cancer.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[{"country":"US","reimbursement":"Medicare covers it for clinical stage T1 to T4a bladder cancer (Veracyte's statement; the MolDX bladder classifier policy L38576 does not name the test)","source":"https://www.veracyte.com/tests/decipher-bladder/providers/","asOf":"2026-11-04"}],"regulatoryEvents":[]},"route":"/drugs/decipher-bladder/","neighbours":{"drug":[{"id":"decipher-prostate","kind":"drug","name":"Decipher Prostate","route":"/drugs/decipher-prostate/"}],"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"technology":[{"id":"gene-expression-prognostic-assays","kind":"technology","name":"Gene-expression prognostic assays","route":"/technologies/gene-expression-prognostic-assays/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"company":[{"id":"veracyte","kind":"company","name":"Veracyte (Decipher)","route":"/companies/veracyte/"}],"paper":[{"id":"paper-seiler-bladder-molecular-subtypes-chemotherapy-eur-urol-2017","kind":"paper","name":"Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy","route":"/key-papers/paper-seiler-bladder-molecular-subtypes-chemotherapy-eur-urol-2017/"}]}}